(Q36164126)

12 August 2017

1 reference

title

Treatment of Guillain-Barré syndrome and CIDP. (English)

1 reference

12 August 2017

main subject

Guillain–Barré syndrome

0 references

1

Pieter A van Doorn

1 reference

12 August 2017

publication date

1 June 2005

1 reference

Journal of the Peripheral Nervous System

12 August 2017

published in

1 reference

12 August 2017

volume

10

1 reference

12 August 2017

issue

2

1 reference

12 August 2017

page(s)

113-127

1 reference

The Guillain-Barré syndrome: a true case of molecular mimicry

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010203.X

Chronic inflammatory demyelinating polyradiculoneuropathy. Clinical characteristics, course, and recommendations for diagnostic criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010203.X

Axonal protection in experimental autoimmune neuritis by the sodium channel blocking agent flecainide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010203.X

Mycophenolate mofetil in dysimmune neuropathies: a preliminary study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010203.X

Psychological diversity in chimpanzees and humans: new longitudinal assessments of chimpanzees' understanding of attention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010203.X

An endogenous pentapeptide acting as a sodium channel blocker in inflammatory autoimmune disorders of the central nervous system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010203.X

IFN-beta decreases adhesion and transmigration capacities of lymphocytes in Guillain-Barré syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010203.X

Immune mediated neuropathies--an update on therapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010203.X

Intravenous immunoglobulin in autoimmune neuromuscular diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010203.X

Immunotherapy of idiopathic inflammatory neuropathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010203.X

A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010203.X

Physical training and fatigue, fitness, and quality of life in Guillain-Barré syndrome and CIDP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010203.X

Functional polymorphisms in LPS receptors CD14 and TLR4 are not associated with disease susceptibility or Campylobacter jejuni infection in Guillain-Barré patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010203.X

HLA class II alleles are not a general susceptibility factor in Guillain-Barré syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010203.X

Epidemiology of the Guillain-Barré syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010203.X

Mild Guillain-Barré syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010203.X

Practical methods for dealing with 'not applicable' item responses in the AMC Linear Disability Score project

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010203.X

Treatment of Guillain-Barré syndrome with corticosteroids: lack of benefit?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010203.X

Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010203.X

Controlled trial prednisolone in acute polyneuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010203.X

Practice parameter: Immunotherapy for Guillain-Barre syndrome: Report of the Quality Standards Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010203.X

Immunoglobulins inhibit pathophysiological effects of anti-GQ1b-positive sera at motor nerve terminals through inhibition of antibody binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010203.X

The spectrum of antecedent infections in Guillain-Barre syndrome: A case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010203.X

Contribution of corticosteroid to the treatment of pain in the acute phase of Guillain-Barré syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010203.X

Distal acquired demyelinating symmetric neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010203.X

Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010203.X

Advances in understanding and treatment of immune-mediated disorders of the peripheral nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010203.X

The treatment of chronic inflammatory demyelinating polyradiculoneuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010203.X

Chronic inflammatory demyelinating polyneuropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010203.X

Therapy of CIDP and related immune-mediated neuropathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010203.X

Comparison of electrodiagnostic abnormalities and criteria in a cohort of patients with chronic inflammatory demyelinating polyneuropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010203.X

Neuromuscular disorders: molecular and therapeutic insights

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010203.X

Cyclosporin A in treatment of refractory patients with chronic inflammatory demyelinating polyradiculoneuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010203.X

Cost-utility analysis of intravenous immunoglobulin and prednisolone for chronic inflammatory demyelinating polyradiculoneuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010203.X

Psychometric evaluation of a new sensory scale in immune-mediated polyneuropathies. Inflammatory Neuropathy Cause and Treatment (INCAT) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010203.X

Clinimetric evaluation of a new overall disability scale in immune mediated polyneuropathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010203.X

Psychometric evaluation of a new handicap scale in immune-mediated polyneuropathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010203.X

Fatigue in immune-mediated polyneuropathies. European Inflammatory Neuropathy Cause and Treatment (INCAT) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010203.X

New cyclooxygenase-2 inhibitors for treatment of experimental autoimmune neuritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010203.X

Chronic inflammatory demyelinating polyneuropathy presenting with features of GBS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010203.X

Mycophenolate (CellCept) treatment of myasthenia gravis, chronic inflammatory polyneuropathy and inclusion body myositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010203.X

Immunoglobulin improves a model of acute motor axonal neuropathy by preventing axonal degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010203.X

Subacute inflammatory demyelinating polyneuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010203.X

Intravenous immune globulins in patients with Guillain-Barré syndrome and contraindications to plasma exchange: 3 days versus 6 days

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010203.X

Chronic inflammatory demyelinative polyneuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010203.X

Research criteria for defining patients with CIDP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010203.X

Effect of methylprednisolone in patients with Guillain-Barré syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010203.X

Growth hormone deficiency (GHD) from birth to 2 years of age: diagnostic specifics of GHD during the early phase of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010203.X

Mycophenolate in treatment-resistant inflammatory neuropathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010203.X

Interferon beta-1a as an investigational treatment for CIDP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010203.X

Diagnostic and classification criteria for the Guillain-Barré syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010203.X

High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010203.X

Treatment of immune neuropathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010203.X

Immunotherapy for Guillain-Barré syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010203.X

Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy. Clinical and laboratory characteristics associated with improvement

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010203.X

Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome: randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010203.X

Mild forms of Guillain-Barré syndrome in an epidemiologic survey in The Netherlands

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010203.X

Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010203.X

Anti–GM1 IgG antibodies induce leukocyte effector functions via Fcγ receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010203.X

FcgammaR polymorphisms: Implications for function, disease susceptibility and immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010203.X

Peripheral neuropathies and anti-glycolipid antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010203.X

Lower limb and back pain in Guillain-Barré syndrome and associated contrast enhancement in MRI of the cauda equina

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010203.X

Carbohydrate mimicry between human ganglioside GM1 and Campylobacter jejuni lipooligosaccharide causes Guillain-Barre syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010203.X

Animal model of axonal Guillain-Barré syndrome induced by sensitization with GM1 ganglioside.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010203.X

Pathology of the motor-sensory axonal Guillain-Barré syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010203.X

Differential Distribution of HLA-DQ /DR Epitopes in the Two Forms of Guillain-Barre Syndrome, Acute Motor Axonal Neuropathy and Acute Inflammatory Demyelinating Polyneuropathy (AIDP): Identification of DQ Epitopes Associated with Susceptibility to an

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1085-9489.2005.0010203.X

10.1111/J.1085-9489.2005.0010203.X

21 January 2018

Identifiers

DOI

1 reference

12 August 2017

1 reference